Old-Age Onset Progressive Cardiac Contractile Dysfunction in a Patient with Polycystic Kidney Disease Harboring a PKD1 Frameshift Mutation.


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
25 Jan 2019
Historique:
pubmed: 23 11 2018
medline: 8 2 2019
entrez: 23 11 2018
Statut: ppublish

Résumé

A 70-year-old man with dyspnea was admitted to our department and received standard therapy for recurrent heart failure. He was diagnosed with polycystic kidney disease (PKD) in his thirties and received hemodialysis for 4 years before undergoing renal transplantation at age 45. Although his left ventricular ejection fraction (LVEF) was preserved in his 50s, LVEF decreased progressively from 61% to 24%, while left ventricular diastolic dimension (LVDd) increased from 54 mm to 65 mm between 63 and 69 years of age. Right ventricular endomyocardial biopsy demonstrated myocardial disarray and interstitial fibrosis. Genetic analysis identified a heterozygous frameshift mutation in PKD1, which encodes polycystin-1, a major causative gene of PKD. We detected PKD1 protein expression in myocardial tissue by immunostaining. Recent epidemiological studies and animal models have clarified the pathological correlation between ventricular contractile dysfunction and PKD1 function. Here, we present a case of old-age onset progressive cardiac contractile dysfunction with a PKD1 gene mutation.

Identifiants

pubmed: 30464138
doi: 10.1536/ihj.18-184
doi:

Substances chimiques

TRPP Cation Channels 0
polycystic kidney disease 1 protein 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

220-225

Commentaires et corrections

Type : CommentIn

Auteurs

Yoshinobu Suwa (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Shuichiro Higo (S)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
Department of Medical Therapeutics for Heart Failure, Osaka University Graduate School of Medicine.

Kei Nakamoto (K)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Fusako Sera (F)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Suzuka Kunimatsu (S)

Department of Medical Therapeutics for Heart Failure, Osaka University Graduate School of Medicine.

Yuki Masumura (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Machiko Kanzaki (M)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Isamu Mizote (I)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Hiroya Mizuno (H)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Yasushi Fujio (Y)

Laboratory of Clinical Science and Biomedicine, Osaka University Graduate School of Pharmaceutical Sciences.

Shungo Hikoso (S)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH